Tissue-resident Immune Cell Subsets in aGVHD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorNanfang Hospital, Southern Medical University
About this trial
This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Voluntarily sign the informed consent form;
Age 16-65 years old
Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.
Disqualifiers
Have a history of other tumors
With poor compliance or mental disorders
Infected with HIV and HCV
With uncontrolled HBV infection
Trial population
Patients develop acute graft-versus-disease after hematopoietic stem cell transplantation.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
40 Participants
are grouped into 2 trial groupsGroup A: Grade 3-4 aGVHD patients
Group B: Grade 1-2 aGVHD patients
Trial outcomes
Primary outcomes
1
Association between tissue-resident Immune cell subsets in organ and acute graft-vs-host disease (aGVHD) outcomes.
Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).
Time frame
100daysSecondary outcomes
1
Association between tissue-resident Immune cell subsets in organ and overall survival(OS).
Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).
Time frame
100days2
Association between tissue-resident Immune cell subsets in organ and disease-free survival (DFS)
Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).
Time frame
100daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov